Abstract
Cardiovascular (CV) disease is one of the most common causes of death in the western populations and, nowadays, its incidence is increasing even in the developing countries; although CV disease affects both sexes, it is more frequent in males in whom it shortens the average life expectancy. In this regard, this difference has been wrongly attributed for many years to the negative effects of testosterone (T); however, nowadays, a large amount of evidence suggests that this hormone may have protective effects on the CV system and that, indeed, the low levels of T could be associated with an increased CV risk and with an augmentation of morbidity and mortality in males. Such an aspect gains great relevance in light of the consideration that T decrease, besides occurring as a consequence of rare pathological conditions, can often take place with natural aging, causing a state of “male menopause”, also called late-onset hypogonadism. In this review, we aimed to summarize the present state of the art concerning the association between T deficit and CV disease by analyzing the protective role of T on CV system and the relationship of this hormonal lack with metabolic syndrome, CV morbidity and mortality, and with the CV complications, such as ischemic heart disease, heart failure and stroke, that frequently occur in T deficiency.
Similar content being viewed by others
Abbreviations
- T:
-
Testosterone
- CV:
-
Cardiovascular
- CAD:
-
Coronary artery disease
- HF:
-
Heart failure
References
Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M (2011) Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 25:337–353. doi:10.1016/j.beem.2010.07.002
Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M (2011) Hypogonadism and metabolic syndrome. J Endocrinol Invest 34:557–567. doi:10.3275/7806
Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8:272–283. doi:10.1111/j.1743-6109.2010.01991.x
Zizzi A, Tirabassi G, Aspriello SD, Piemontese M, Rubini C, Lucarini G (2012) Gingival advanced glycation end-products in diabetes mellitus-associated chronic periodontitis: an immunohistochemical study. J Periodontal Res. doi:10.1111/jre.12007
Marcellini F, Giuli C, Papa R, Tirabassi G, Faloia E, Boscaro M, Polito A, Ciarapica D, Zaccaria M, Mocchegiani E (2009) Obesity and body mass index (BMI) in relation to life-style and psycho-social aspects. Arch Gerontol Geriatr 49(Suppl 1):195–206. doi:10.1016/j.archger.2009.09.029
Faloia E, Tirabassi G, Canibus P, Boscaro M (2009) Protective effect of leg fat against cardiovascular risk factors in obese premenopausal women. Nutr Metab Cardiovasc Dis 19:39–44. doi:10.1016/j.numecd.2008.02.004
Phillips GB, Castelli WP, Abbott RD, McNamara PM (1983) Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med 74:863–869
English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS (2000) Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 21:890–894
Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Volterrani M, Aversa A, Fini M (2007) Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 19:176–182
Jeppesen LL, Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS, Winther K (1996) Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 16:749–754
Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, Flicker L, Hankey GJ (2009) Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 94:2353–2359. doi:10.1210/jc.2008-2416
Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 116:2694–2701
Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M (2010) Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 7:1557–1564. doi:10.1111/j.1743-6109.2009.01690.x
Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:687–701. doi:10.1530/EJE-11-0447
Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA (2011) Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 96:3007–3019. doi:10.1210/jc.2011-1137
Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54:919–927. doi:10.1016/j.jacc.2009.04.078
Webb CM, Adamson DL, de Zeigler D, Collins P (1999) Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83:437–439
Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ (2001) Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281:1720–1727
Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS (2002) Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol 39:814–823
Corrales JJ, Almeida M, Burgo R, Mories MT, Miralles JM, Orfao A (2006) Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189:595–604
Nettleship JE, Jones TH, Channer KS, Jones RD (2007) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 116:2427–2434
Tharp DL, Masseau I, Ivey J, Ganjam VK, Bowles DK (2009) Endogenous testosterone attenuates neointima formation after moderate coronary balloon injury in male swine. Cardiovasc Res 82:152–160. doi:10.1093/cvr/cvp038
Maddali KK, Korzick DH, Tharp DL, Bowles DK (2005) PKCdelta mediates testosterone-induced increases in coronary smooth muscle Cav1.2. J Biol Chem 280:43024–43029
Jin H, Lin J, Fu L, Mei YF, Peng G, Tan X, Wang DM, Wang W, Li YG (2007) Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol 85:246–251
Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 7:1627–1656. doi:10.1111/j.1743-6109.2010.01780.x
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tirabassi, G., Gioia, A., Giovannini, L. et al. Testosterone and cardiovascular risk. Intern Emerg Med 8 (Suppl 1), 65–69 (2013). https://doi.org/10.1007/s11739-013-0914-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-013-0914-1